Skip to main content
Premium Trial:

Request an Annual Quote

FDA Clears Osmetech's Warfarin Sensitivity Test

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has cleared for marketing Osmetech’s eSensor Warfarin Sensitivity Test, the London-based firm announced today.
 
The genetic test is used to aid physicians in identifying patients who are at risk for increased sensitivity to the blood-thinning drug warfarin. Osmetech submitted its application with the FDA for the test at the beginning of this year.
 
The firm said that the FDA also cleared its second-generation eSensor XT-8 molecular diagnostics platform.
 
Osmetech is the latest of several firms that have received FDA clearance over the past 10 months for molecular-based warfarin sensitivity assays. The other firms include Nanosphere, which was the first company to receive clearance, Autogenomics, and ParagonDx.
 
The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.